Monitoring disease activity by stool analyses: From occult blood to molecular markers of intestinal inflammation and damage

Gut

Volumn 58, Issue 6, 2009, Pages 859-868

  Foell, D ^a   Wittkowski, H ^a   Roth, J ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN A; CALGRANULIN B; EOSINOPHIL CATIONIC PROTEIN; LACTOFERRIN; MYELOPEROXIDASE; PATTERN RECOGNITION RECEPTOR; PROTEIN S 100; PROTEIN S 100A12; PROTEIN X; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

DISEASE ACTIVITY; DISEASE MARKER; ENTERITIS; FECES ANALYSIS; HUMAN; INTESTINE INJURY; MONOCYTE; NEUTROPHIL; OCCULT BLOOD; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; CYTOKINES; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LEUKOCYTE L1 ANTIGEN COMPLEX; OCCULT BLOOD; PROTEOMICS; S100 PROTEINS;

EID: 66649100476     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.170019     Document Type: Review

References (101)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-434 (Pubitemid 47123518)
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-429
3. Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996;379:821-823 (Pubitemid 26067722)
4. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603. (Pubitemid 32531408)
5. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002;359:1661-1665 (Pubitemid 34518526)
6. Girardin SE, Hugot JP, Sansonetti PJ. Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. Trends Immunol 2003;24:652-658 (Pubitemid 37485915)
7. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55:426-431
8. Niederau C, Backmerhoff F, Schumacher B. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology 1997;44:90-107. (Pubitemid 27096020)
9. Nielsen OH, Vainer B, Madsen SM, et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 2000;95:359-367 (Pubitemid 30106162)
10. Cummings JR, Keshav S, Travis SP. Medical management of Crohn's disease. BMJ (Clin Res) 2008;336:1062-1066
11. Brignola C, Lanfranchi GA, Campieri M, et al. Importance of laboratory parameters in the evaluation of Crohn's disease activity. J Clin Gastroenterol 1986;8(3 Pt 1):245-248 (Pubitemid 16054165)
12. Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793-798
13. de Jong NS, Leach ST, Day AS. Fecal S100A12: a novel noninvasive marker in children with Crohn's disease. Inflam Bowel Dis 2006;12:566-572 (Pubitemid 43977737)
14. Uchida K, Matsuse R, Tomita S, et al. Immunochemical detection of human lactoferrin in feces as a new marker for inflammatory gastrointestinal disorders and colon cancer. Clin Biochem 1994;27:259-264 (Pubitemid 24300418)
15. Sugi K, Saitoh O, Hirata I, et al. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996;91:927-934 (Pubitemid 26143531)
16. van der Sluys Veer A, Biemond I, Verspaget HW, et al. Faecal parameters in the assessment of activity in inflammatory bowel disease. Scand J Gastroenterol Suppl 1999;230:106-110 (Pubitemid 29434518)
17. de Silva DG, Mendis LN, Sheron N, et al. Concentrations of interleukin 6 and tumour necrosis factor in serum and stools of children with Shigella dysenteriae 1 infection. Gut 1993;34:194-198 (Pubitemid 23049111)
18. Larsen A, Hovdenak N, Karlsdottir A, et al. Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers. Scand J Gastroenterol 2004;39:1113-1118 (Pubitemid 39536401)
19. Peterson CG, Eklund E, Taha Y, et al. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol 2002;97:1755-1762 (Pubitemid 34761402)
20. Olafsdottir E, Aksnes L, Fluge G, et al. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr 2002;91:45-50. (Pubitemid 34151218)
21. Carroll D, Corfield A, Spicer R, et al. Faecal calprotectin concentrations and diagnosis of necrotising enterocolitis. Lancet 2003;361:310-311 (Pubitemid 36126194)
22. Josefsson S, Bunn SK, Domellof M. Fecal calprotectin in very low birth weight infants. J Pediatr Gastroenterol Nutr 2007;44:407-413 (Pubitemid 46573221)
23. Campeotto F, Kalach N, Lapillonne A, et al. Time course of faecal calprotectin in preterm newborns during the first month of life. Acta Paediatr 2007;96:1531-1533 (Pubitemid 47416431)
24. Greegor DH. Occult blood testing for detection of asymptomatic colon cancer. Cancer 1971;28:131-134
25. Biancone L, Fantini M, Tosti C, et al. Fecal alpha 1-antitrypsin clearance as a marker of clinical relapse in patients with Crohn's disease of the distal ileum. Eur J Gastroenterol Hepatol 2003;15:261-266 (Pubitemid 36337846)
26. Fischbach W, Becker W, Mossner J, et al. Faecal alpha-1-antitrypsin and excretion of 111indium granulocytes in assessment of disease activity in chronic inflammatory bowel diseases. Gut 1987;28:386-393 (Pubitemid 17056871)
27. Saitoh O, Matsumoto H, Sugimori K, et al. Intestinal protein loss and bleeding assessed by fecal hemoglobin, transferrin, albumin, and alpha-1-antitrypsin levels in patients with colorectal diseases. Digestion 1995;56:67-75.
28. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50-54 (Pubitemid 29074787)
29. Peterson CG, Sangfelt P, Wagner M, et al. Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scand J Clin Lab Invest 2007;67:810-820 (Pubitemid 350158774)
30. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
31. Lettesjo H, Hansson T, Peterson C, et al. Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis. Scand J Gastroenterol 2006;41:54-59 (Pubitemid 43030892)
32. Nielsen OH, Gionchetti P, Ainsworth M, et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 1999;94:2923-2928 (Pubitemid 29482759)
33. Nicholls S, Stephens S, Braegger CP, et al. Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol 1993;46:757-760 (Pubitemid 23242431)
34. Bischoff SC, Mayer J, Nguyen QT, et al. Immunohistological assessment of intestinal eosinophil activation in patients with eosinophilic gastroenteritis and inflammatory bowel disease. Am J Gastroenterol 1999;94:3521-3529
35. Saitoh O, Kojima K, Sugi K, et al. Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease. Am J Gastroenterol 1999;94:3513-3520
36. Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and Am J Gastroenterol 2008;103(1):162-169
37. Langhorst J, Elsenbruch S, Mueller T, et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 2005;11:1085-1091 (Pubitemid 41682565)
38. Nielsen BS, Borregaard N, Bundgaard JR, et al. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 1996;38:414-420 (Pubitemid 126423216)
39. Walker TR, Land ML, Kartashov A, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:414-422 (Pubitemid 46573222)
40. Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica 1995;80:252-267
41. Ward PP, Uribe-Luna S, Conneely OM. Lactoferrin and host defense. Biochem Cell Biol 2002;80:95-102.
42. Suzuki YA, Shin K, Lonnerdal B. Molecular cloning and functional expression of a human intestinal lactoferrin receptor. Biochemistry 2001;40:15771-15779 (Pubitemid 34015206)
43. Crouch SP, Slater KJ, Fletcher J. Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood 1992;80:235-240
44. Togawa J, Nagase H, Tanaka K, et al. Oral administration of lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. J Gastroenterol Hepatol 2002;17:1291-1298 (Pubitemid 35356966)
45. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leuk Biol 2007;81:1-5. (Pubitemid 46028489)
46. Foell D, Kucharzik T, Kraft M, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003;52:847-853 (Pubitemid 36613492)
47. Foell D, Wittkowski H, Ren Z, et al. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol 2008;216:183-192
48. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med 2000;343:338-344
49. Ulevitch RJ. Therapeutics targeting the innate immune system. Nat Rev Immunol 2004;4:512-520 (Pubitemid 38931766)
50. Hugot JP. CARD15/NOD2 mutations in Crohn's disease. Ann N Y Acad Sci 2006;1072:9-18. (Pubitemid 44448439)
51. Levine AD, Fiocchi C. Immunology of inflammatory bowel disease. Curr Opin Gastroenterol 2000;16:306-309 (Pubitemid 32260399)
52. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007;7:179-190 (Pubitemid 46310482)
53. Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol 2003;4:95-104. (Pubitemid 36172693)
54. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006;442:39-44. (Pubitemid 44064203)
55. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008;8:279-289
56. Foell D, Wittkowski H, Roth J. Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nat Clin Pract Rheumatol 2007;3:382-390
57. Foell D, Wittkowski H, Vogl T, et al. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leuk Biol 2007;81:28-37. (Pubitemid 46021248)
58. Hofmann MA, Drury S, Fu CF, et al. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell Jun 1999;97:889-901. (Pubitemid 29375048)
59. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007;13:1042-1049 (Pubitemid 47517513)
60. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-342 (Pubitemid 40516158)
61. Heizmann CW, Fritz G, Schafer BW. S100 proteins: structure, functions and pathology. Front Biosci 2002;7:d1356-68.
62. Leukert N, Vogl T, Strupat K, et al. Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity. J Mol Biol 2006;359:961-972 (Pubitemid 43831924)
63. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004;50:3762-3771 (Pubitemid 39643922)
64. Roth J, Vogl T, Sorg C, et al. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol 2003;24:155-158 (Pubitemid 36412096)
65. Vogl T, Propper C, Hartmann M, et al. S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J Biol Chem 1999;274:25291-25296 (Pubitemid 129530693)
66. 2+-binding proteins S100A8 and S100A9 are encoded by novel injury-regulated genes. J Biol Chem 2001;276:35818-35825
67. Rammes A, Roth J, Goebeler M, et al. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997;272:9496-9502 (Pubitemid 27154966)
68. Schmidt AM, Yan SD, Yan SF, et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-955 (Pubitemid 32946067)
69. Viemann D, Barczyk K, Vogl T, et al. MRP8/MRP14 impairs endothelial integrity and induces a caspase-dependent and - independent cell death program. Blood 2007;109:2453-2460 (Pubitemid 46425888)
70. Newton RA, Hogg N. The human S100 protein MRP-14 is a novel activator of the beta(2) integrin Mac-1 on neutrophils. J Immunol 1998;160:1427-1435
71. Viemann D, Strey A, Janning A, et al. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood 2005;105:2955-2962 (Pubitemid 40446292)
72. Wittkowski H, Sturrock A, van Zoelen MA, et al. Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med 2007;35:1369-1375 (Pubitemid 46642668)
73. Lugering N, Stoll R, Kucharzik T, et al. Immunohistochemical distribution and serum levels of the Ca(2+)-binding proteins MRP8, MRP14 and their heterodimeric form MRP8/14 in Crohn's disease. Digestion 1995;56:406-414
74. Rugtveit J, Haraldsen G, Hogasen AK, et al. Respiratory burst of intestinal macrophages in inflammatory bowel disease is mainly caused by CD14+L1+ monocyte derived cells. Gut 1995;37:367-373
75. Srikrishna G, Turovskaya O, Shaikh R, et al. Carboxylated glycans mediate colitis through activation of NF-kappa B. J Immunol 2005;175:5412-5422 (Pubitemid 41456427)
76. Leach ST, Yang Z, Messina I, et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 2007;42:1321-1331 (Pubitemid 47537067)
77. D'Inca R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007;22:429-437 (Pubitemid 46336248)
78. Dolwani S, Metzner M, Wassell JJ, et al. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Alim Pharmacol Therap 2004;20:615-621 (Pubitemid 39279049)
79. Fagerberg UL, Loof L, Myrdal U, et al. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005;40:450-455 (Pubitemid 40489572)
80. Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706-1713 (Pubitemid 350206297)
81. Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003;49(6 Pt 1):861-867 (Pubitemid 36623463)
82. Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 2000;95:2831-2837
83. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-513
84. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-460 (Pubitemid 34827189)
85. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803-813 (Pubitemid 46496634)
86. Schroder O, Naumann M, Shastri Y, et al. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther 2007;26:1035-1042 (Pubitemid 47416301)
87. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40-46
88. Montalto M, Curigliano V, Santoro L, et al. Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. Am J Gastroenterol 2007;102:132-136 (Pubitemid 46072053)
89. Thjodleifsson B, Sigthorsson G, Cariglia N, et al. Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology 2003;124:1728-1737
90. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005;54:364-368 (Pubitemid 40299092)
91. Diamanti A, Colistro F, Basso MS, et al. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis 2008;14:1229-1235
92. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22. (Pubitemid 30452574)
93. Sipponen T, Savilahti E, Karkkainen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008;14:1392-1398
94. Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008;40:547-553
95. D'Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008;103:2007-2014
96. Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis 2008;14:359-366
97. Ward PP, Paz E, Conneely OM. Multifunctional roles of lactoferrin: a critical overview. Cell Mol Life Sci 2005;62:2540-2548 (Pubitemid 41721229)
98. Poullis A, Foster R, Shetty A, et al. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2004;13:279-284 (Pubitemid 38222561)
99. Walkiewicz D, Werlin SL, Fish D, et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008;14:669-673
100. Damms A, Bischoff SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int J Colorectal Dis 2008;23:985-992
101. Otten CM, Kok L, Witteman BJ, et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med 2008;46:1275-1280